PEOPLE
Research Staff
Scientific Advisory Board
Executive Management Board
Research Staff
Guido Tarone
Co-founder
Is Full Professor of Cell Biology at the University of Turin Medical School. In his career he spent several periods in prestigious scientific institutions in USA among which: Department of Pathology, Yale University (1976-1977), The Winstar Institute, Philadelpha (1983), La Jolla Cancer Research Foundation (now The Burhnam Cancer Institute), San Diego (1989), Department of Pathology, Columbia University, New York (2000). His research interest is focused on membrane protein function and receptor signaling pathways and his expertise and contribution in the field of integrin signaling is internationally recognized. His research interest is focused on the signaling mechanisms controlling heart and muscle hypertrophy. He is author of 110 scientific papers quoted on ISI citation report. He is President of the Italian Association of Cell Biology and Differentiation.
Giuseppe Lembo
Co-founder
Is Associated Professor of Internal Medicine at the University of Rome “La Sapienza” and Head of the Angio-Cardiology Department at IRCCS Neuromed (Molise). In 1993-1994 he was at the Department of Medicine and Center for Molecular Genetics, University of California San Diego in the laboratory of KR Chien. He is Member of the Editorial Board of “Journal of Hypertension” and his research interest are the molecular mechanisms involved in heart failure, a topic in which he is internationally recognized as demonstrated by numerous invitation to international meetings and its reviewer activity for the leading journals in the field. He is author of 100 scientific papers quoted on ISI citation report. He has a long standing experience both in clinical and experimental cardiology.
Mara Brancaccio
Co-founder
Research Scientist at the University of Turin Medical School. Since 1996 she has been working on the project that has led to melusin discovery and she spent a year training at the Harvard Medical School, MGH, Boston, USA in the laboratory of Prof. G.P. Dotto. In 1999 she won the national prize of the Italian Federation of Life Sciences (FISV) for the best Ph.D. thesis in Cell Biology. She has gained a great expertise in molecular biology technologies and analysis of signal transduction pathways.
Federica Accornero
She got a Master degree in Biotechnology at the University of Turin and her thesis work greatly contributed to the development of the analysis of melusin signaling in cardiomyocytes and to the development of viral vectors for experimental gene therapy approaches. Her strong technical and scientific expertise in molecular and cell biology is key to the development of the Target Heart research project.
Sara Saponaro
She got Master degree in Biology at the University of Turin. She has a good experience in cell culture as well as in biochemical and immunochemical analysis of cellular proteins that is key to the generation and preparation of specific melusin constructs.
Scientific Advisory Board
Silvano Fumero
CEO of Creabilis Therapeutics SpA (Ivrea, Italy)
Former Senior Executive Vice President of Serono, Geneva, Head of Research and Pharmaceutical Development since April 1996 till April 2003. From 1991 to 1996 responsible of LCG Bioscience, a European network, based in London, of contract research labs and clinics in the field of drug development, specifically toxicology, pharmacokinetics, metabolism and phase I. General Manager of RBM from 1987 to 1991. Various research positions including two years, 1982 and 1983, as toxicologist at the Directorate Chemical and Pharma Industry of the European Commission in Brussels. In total more than 35 years in the field of research and development of the pharma/biotech sector.
Silvio Traversa
Scientist at Creabilis Therapeutics SpA (Ivrea, Italy)
Ph.D. in Protein Chemistry in February 1999 from the University of Turino. In February 1999, he joined Industria Farmaceutica Serono S.p.A. in Colleretto Giacosa - Ivrea (Italy) as Junior Researcher. He spent six years in the Drug Delivery Systems department at Serono, working at several project in the field of bioconjugation of peptides and proteins. He worked as Peptide and Protein Analysis Laboratory Head and as Protein Pre-Formulation Team Leader, being involved in projects regarding proteins at the Hit-to-Lead and Pre-Clinical Development stages.
Gianni Garotta
CEO of RiboVax Biotechnologies SA (Geneva, Switzerland)
Former investigator at the General Pathology Institute of the University of Milan, the Wistar Institute, the Italian National Cancer Institute (Milan, Italy) and the Basel Institute of Immunology. He was the Head of the Cytokine and Monoclonal Antibody groups at Roche (Basel, Switzerland) and the Head of Biology and Human Genome Sciences (Rockville, MD, USA). Most recently, he was the Vice President of Extramural Research and Academic Collaborations at Serono International (Geneva, Switzerland). Dr Garotta has 25 year experience in discovery and development of pharmaceutical and biological products and has been involved in numerous academic and industrial collaborations.
Angelo Conz
Senior Scientific Advisor Serono Consultant
Former Vice President of Serono, Geneva, Head of Global Product Development Unit Dermatology and New Therapies since Oct. 2002 till Dec. 2006. From 1996 to 2002 responsible of LCG Bioscience, a European network, based in London, of contract research labs and clinics in the field of drug development. General Manager of RBM from 1991 to 1996; Pathological Anatomy, Histopathology, Mutagenesis and Immunotoxicology Department Head of RBM from 1984 to 1991; Pathological Anatomy and Histopathology Department Head of Dow Chemical/Lepetit, Toxicology Center from 1971 to 1983.
Executive Management Board
Guido Tarone - President and CEO
Luigi Stabile - General Councel
Roberto Berutti - General Councel
|
